Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in bDMARD-naïve patients with pSoriatic arthriTis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512459-19-00

Enrollment

129

Registered

2024-06-11

Start date

2024-09-13

Completion date

Unknown

Last updated

2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic arthritis

Brief summary

Resolution of enthesitis (SPARCC = 0) at week 24

Interventions

DRUGTremfya 100 mg solution for injection in pre-filled pen.

DRUGTremfya 100 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Resolution of enthesitis (SPARCC = 0) at week 24	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026